HCW Biologics is developing immunotherapies to lengthen healthspan by disrupting the link between cellular senescence and disease.
HCW Biologics has raised $1.6M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2026.
HCW Biologics's investors include Lee Flowers, Scott T. Garrett, DeepWork Capital, Hing C. Wong.
HCW Biologics is headquartered in Miramar Beach, United States.
HCW Biologics is developing immunotherapies to lengthen healthspan by disrupting the link between cellular senescence and disease.
HCW Biologics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"HCW Biologics — Funding & Investors." VCBacked, July 29, 2026, https://www.vcbacked.co/company/hcw-biologics. Accessed September 21, 2026.
VCBacked. (2026). HCW Biologics — Funding & Investors. Retrieved September 21, 2026, from https://www.vcbacked.co/company/hcw-biologics
{{cite web |title=HCW Biologics — Funding & Investors |url=https://www.vcbacked.co/company/hcw-biologics |website=VCBacked |access-date=September 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated